But FitzGerald and Holmboe favor another, cheaper approach: finding out more about the basic science to see if it's possible to figure out which patients would be most at risk.
"It's not any different from what we knew back in February, " says Eric Holmboe , a vice president for evaluation research at the American Board of Internal Medicine who served on the Food and Drug Administration panel that looked at the risks of common pain drugs.